Patents Assigned to Bioagency AG
-
Publication number: 20130231296Abstract: The present invention relates to pharmaceutical preparations/compositions comprising 3-N-formyl hydroxy amino propyl phosphonic acid derivatives or 3-N-acetyl hydroxy amino propyl phosphonic acid derivatives as active ingredients in combination with Piperaquine.Type: ApplicationFiled: July 6, 2011Publication date: September 5, 2013Applicant: Bioagency AGInventors: David Hutchinson, Winston Gutteridge
-
Publication number: 20110129883Abstract: The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments.Type: ApplicationFiled: January 18, 2011Publication date: June 2, 2011Applicant: BIOAGENCY AGInventors: HASSAN JOMAA, MATTHIAS EBERL, BORAN ALTINCICEK
-
Publication number: 20110112054Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: January 17, 2011Publication date: May 12, 2011Applicant: BIOAGENCY AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Patent number: 7875279Abstract: The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments.Type: GrantFiled: April 13, 2002Date of Patent: January 25, 2011Assignee: Bioagency AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek
-
Patent number: 7871992Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: GrantFiled: June 11, 2008Date of Patent: January 18, 2011Assignee: Bioagency AGInventors: Hassan Jomaa, Oliver Wolf, Boran Altincicek, Mathias Eberl, Martin Hintz, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20080318942Abstract: The invention relates to new fredericamycin derivatives, to pharmaceutical drugs containing them or their salts, and to the use of the fredericamycin derivatives for the treatment of diseases, especially tumor diseases.Type: ApplicationFiled: September 1, 2006Publication date: December 25, 2008Applicants: BIOAGENCY AG, DISCOVERY PARTNERS INTERNATIONAL GMBHInventors: Werner Simon, Rajendra-Prasad Maskey, Hans-Falk Rasser, Bernd Sontag, Peter Eckard, Iris- Grun-Wollny, Friedrich Hansske, Bjorn Friedrich Lindemann
-
Publication number: 20080249067Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: June 11, 2008Publication date: October 9, 2008Applicant: Bioagency AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20080206267Abstract: The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments.Type: ApplicationFiled: April 13, 2002Publication date: August 28, 2008Applicant: BIOAGENCY AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek
-
Patent number: 7399756Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: GrantFiled: July 18, 2002Date of Patent: July 15, 2008Assignee: Bioagency AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner